Reactive oxygen species and nitric oxide in viral diseases

Biological Trace Element Research

Volumn 56, Issue 1, 1997, Pages 107-116

  Peterhans, Ernst ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

antioxidants; cytokines; hepatitis; HIV; influenza; metabolism; nitric oxide; physiology; therapy; Virus

Indexed keywords

CONFERENCE PAPER; DIET SUPPLEMENTATION; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; INFLUENZA VIRUS; LIVER CANCER; METABOLISM; NONHUMAN; OXIDATIVE STRESS; PARAMYXOVIRUS; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS PATHOGENESIS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN INFLUENZA VIRUS; INFLUENZA VIRUS; PARAMYXOVIRIDAE;

EID: 0030979523     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02778986     Document Type: Conference Paper

References (75)

1. D. S. Bredt, and S. H. Snyder, Nitric oxide: a physiologic messenger molecule, Annu. Rev. Biochem, 63, 175-195 (1994).
2. J. L. Zweier, P. Wang, A. Samouilov, and P. Kuppusamy, Enzyme-independent formation of nitric oxide in biological tissues (see comments), Nature Med. 1, 804-809 (1995).
3. V. Darley-Usmar, H. Wiseman, and B. Halliwell, Nitric oxide and oxygen radicals: a question of balance, FEBS Lett. 369, 131-135 (1995).
4. B. Halliwell, J. M. C. Gutteridge, and C. E. Cross, Free radicals, antioxidants, and human disease - where are we now, J. Lab. Clin. Med. 119, 598-620 (1992).
5. R. H. Burdon, Superoxide and hydrogen peroxide in relation to mammalian cell proliferation, Free Radical Biol. Med. 18, 775-794 (1995).
6. M. E. Belding, S. J. Klebanoff, and C. G. Ray, Peroxidase-Mediated virucidal systems, Science 167, 195-196 (1970).
7. E. F. Wheelock, and S. T. Toy, Participation of lymphocytes in viral infections, Adv. Immunol. 16, 123-184 (1973).
8. J. F. Woodruff, and J. J. Woodruff, T lymphocyte interaction with viruses and virus-infected tissues, Prog. Med. Virol. 19, 120-160 (1975).
9. G. M. Butchko, R. B. Armstrong, W. J. Martin, and F. A. Ennis, Influenza A viruses of the H2N2 subtype are lymphocyte mitogens, Nature 271, 65-67 (1978).
10. E. Peterhans, E. Haenggeli, P. Wild, and R. Wyler, Mitochondrial calcium uptake during infection of chicken embryo fibroblasts with Semliki Forest virus, J. Virol. 29, 143-152 (1979).
11. E. Peterhans, Sendai virus stimulates chemiluminescence in mouse spleen cells, Biochem. Biophys. Res. Commun. 91, 383-392 (1979).
12. E. Peterhans, Chemiluminescence: an early event in the interaction of Sendai and influenza viruses with mouse spleen cells. I. The role of the envelope glycoproteins in the stimulation of chemiluminescence, Virology 105, 445-455 (1980).
13. W. Henle, and G. Henle, The toxicity of influenza virus, Science 102, 398-400 (1945).
14. I. L. Bennet, R. R. Wagner, and V. S. Lequire, Pyrogenicity of influenza virus in rabbits, Proc. Soc. Exp. Biol. Med. 71, 132-133 (1949).
15. J. M. Edney, Studies on the toxicity of influenza viruses, PhD thesis, University of London (1955).
16. E. Peterhans, F. Mettler, and E. Manser, The effect of virus particle size on chemiluminescence induction by influenza and Sendai-viruses in mouse spleen cells, Free Radical Res. Commun. 11, 11-22 (1990).
17. E. Peterhans, M. Grob, T. Bürge, and R. Zanoni, Virus-induced formation of reactive oxygen intermediates in phagocytic cells, Free Radical Res. Commun. 3, 39-46 (1987).
18. E. Peterhans, T. W. Jungi, and R. Stocker, Autotoxicity and reactive oxygen in viral disease, in Oxy-Radicals in Molecular Biology and Pathology, UCLA Symposia on Molecular and Cellular Biology, New Series, vol. 82, P. A. Cerutti, I. Fridovich, and J. M. McCord, eds., pp. 543-562 (1988).
19. G. D. Buffinton, S. Christen, E. Peterhans, and R. Stocker, Oxidative stress in lungs of mice infected with influenza A virus, Free Radical Res. Commun. 16, 99-110 (1992).
20. T. Hennet, E. Peterhans, and R. Stocker, Alterations in antioxidant defences in lung and liver of mice infected with influenza A virus, J. Gen. Virol. 73, 39-46 (1992).
21. T. Oda, T. Akaike, T. Hamamoto, F. Suzuki, T. Hirano, and H. Maeda, Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymerconjugated SOD, Science 244, 974-976 (1989).
22. P. S. Morahan, A. Pinto, D. Stewart, D. M. Murasko, and M. A. Brinton, Varying role of alpha/beta interferon in the antiviral efficacy of synthetic immunomodulators against Semliki Forest virus infection, Antiviral Res. 15, 241-254 (1991).
23. S. C. Kunder, L. Wu, and P. S. Morahan, Protection against murine cytomegalovirus infection in aged mice and mice with severe combined immunodeficiency disease with the biological response modifiers polyribosinic-polycytidylic acid stabilized with L-lysine and carboxymethylcellulose, maleic anhydride divinyl ether and colony stimulating factor 1, Antiviral Res. 21, 233-245 (1993).
24. N. O. Bykova, N. V. Gorbunov, A. A. Bolgarev, M. V. Savina, T. I. Ivanova, M. A. Egoiants, V. F. Vanin, and M. P. Prozorovskaia, Oxidative phosphorylation in liver mitochondria in toxic form of experimental form of influenza, Biull. Eksp. Biol. Med. 112, 617-619 (1991).
25. T. Akaike, Y. Noguchi, S. Ijiri, K. Setoguchi, M. Suga, Y. M. Zheng, B. Dietzschold, and H. Maeda, Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals, Proc. Natl. Acad. Sci. USA 93, 2448-2453 (1996).
26. K. G. Nicholson, Clinical features of Influenza, Semin. Respir. Infect. 7, 26-37 (1992).
27. S. Ansher, W. Thompson, and W. Habig, Vaccine-induced alterations in hepatic drug metabolism, Vaccine 9, 277-283 (1991).
28. T. Hennet, H. J. Ziltener, K. Frei, and E. Peterhans, A kinetic study of immune mediators in the lungs of mice infected with iinfluenza-A virus, J. Immunol. 149, 932-939 (1992).
29. I. Dvoretzky, Flulike symptoms with interferon, J. Am. Acad. Dermatol. 22, 321-322 (1990).
30. S. J. Klebanoff, and R. W. Coombs, Viricidal effect of polymorphonuclear leukocytes on human immunodeficiency virus-1 - role of the myeloperoxidase system, J. Clin. Invest. 89, 2014-2017 (1992).
31. R. Rott, H. D. Klenk, Y. Nagai, and M. Tashiro, Influenza viruses, cell enzymes, and pathogenicity, Am. J. Respir. Crit. Care Med. 152, 4 Suppl., S16-S19 (1995).
32. H. Kido, K. Sakai, Y. Kishino, and M. Tashiro, Pulmonary surfactant is a potential endogenous infibitor of proteolytic activation of Sendai and influenza a virus, FEBS Lett. 322, 115-119 (1993).
33. K. McCusker, Mechanisms of respiratory tissue injury from cigarette smoking, Am. J. Med. 93 (1A), 18S-21S (1992).
34. F. L. Ruben, and T. R. Cate, Influenza pneumonia, Semin. Respir. Infect. 2, 122-129 (1987).
35. W. Dröge, H. P. Eck, and S. Mihm, Oxidant-antioxidant status in human immunodeficiency virus infection, Oxygen radicals in biological systems, Methods Enzymol. 233, 594-601 (1994).
36. D. J. Malvy, M. J. Richard, J. Arnaud, A. Favier, and O. Amedee Manesme, relationship of plasma malondialdehyde, vitamin E and antioxidant micronutrients to human immunodeficiency virus-1 seropositivity, Clin. Chim. Acta 224, 89-94 (1994).
37. J. Fuchs, I. Emerit, A. Levy, L. Cernajvski, H. Schofer, and R. Milbradt, Clastogenic factors in plasma of HIV-1 infected patients, Free Radical Biol. Med. 19, 843-848 (1995).
38. J. Piette, and S. Legrand Poels, HIV-1 reactivation after an oxidative stress mediated by different reactive oxygen species, Chem. Biol. Interact. 91, 79-89 (1994).
39. B. Piret, S. Legrand Poels, C. Sappey, and J. Piette, NF-Kappa B transcription factor and human immunodeficiency virus type 1 (HIV-1) activation by methylene blue photosensitization, Eur. J. Biochem. 228, 447-455 (1995).
40. R. Schreck, P. Rieber, and P. A. Baeuerle, Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-Kappa-B transcription factor and HIV-1, EMBO J. 10, 2247-2258 (1991).
41. T. Hennet, C. Richter, and E. Peterhans, Tumour necrosis factor-alpha induces superoxide anion generation in mitochondria of L929 cells, Biochem. J. 289, 587-592 (1993).
42. V. B. O'Donnell, S. Spycher, and A. Azzi, Involvement of oxidants and oxidant-generating enzyme(s) in tumour-necrosis-factor-alpha-mediated apoptosis: role for lipoxygenase pathway but not mitochondrial respiratory chain, Biochem. J. 310, 133-141 (1995).
43. D. Pietraforte, E. Tritarelli, U. Testa, and M. Minetti, Gp120 HIV envelope glycoprotein increases the production of nitric oxide in human monocyte-derived macrophages, J. Leukocyte Biol. 55, 175-182 (1994).
44. M. O. Westendorp, V. A. Shatrov, K. Schulze Osthoff, R. Frank, M. Kraft, M. Los, P. H. Krammer, W. Droge, and V. Lehmann, HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state, Embo J. 14, 546-554 (1995).
45. S. Arai, T. Munakata, and K. Kuwano, Mycoplasma interaction with lymphocytes and phagocytes: role of hydrogen peroxide released from M. pneumoniae, Yale J. Biol. Med. 56, 631-638 (1983).
46. P. Köppel, E. Peterhans, G. Bertoni, R. Keist, P. Groscurth, R. Wyler, and R. Keller, Induction of chemiluminescence during interaction of tumoricidal effector cell populations and tumor cells is dependent on the presence of mycoplasma, J. Immunol. 132, 2021-2029 (1984).
47. J. Chochola, A. D. Strosberg, and M. Stanislawski, Release of hydrogen peroxide from human T cell lines and normal lymphocytes co-infected with HIV-1 and mycoplasma, Free Radical Res. 23, 197-212 (1995).
48. G. W. Pace, and C. D. Leaf, The role of oxidative stress in HIV disease, Free Radical Biol. Med. 19, 523-528 (1995).
49. M. L. Linial, and M. Emerman, RNA tumor virus update, Cancer Cells - A Monthly Rev. 3, 351-354 (1991).
50. K. H. Vousden, and P. J. Farrell, Viruses and human Cancer, Br. Med. Bull. 50, 560-581 (1994).
51. Anonymus. The A to F of viral hepatitis, Lancet 336, 1158-1160 (1990).
52. A. J. Zuckerman, The new GB hepatitis viruses, Lancet 345, 1453-1454 (1995).
53. D. R. Milich, J. Jones, J. Hughes, and T. Maruyama, Hepatitis B virus infection, the immune response and hepatocellular carcinoma, Ciba Found. Symp, 187, 113-129 (1994).
54. H. Ohshima, and H. Bartsch, Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis, Mutat. Res. 305, 253-264 (1994).
55. B. N. Ames, L. S. Gold, and W. C. Willett, The causes and prevention of cancer, Proc. Natl. Acad. Sci. USA 92, 5258-5265 (1995).
56. R. Rott, S. Herzog, B. Fleischer, A. Winokur, J. Amsterdam, W. Dyson, and H. Koprowski, Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders, Science 228, 755-756 (1985).
57. M. Z. Yong, M. K. H. Schafer, E. Weihe, S. Hai, S. Corisdeo, F. F. Zhen, H. Koprowski, and B. Dietzschold, Severity of neurological signs and degree of inflammatory lesions in the brains of rats with Borna disease correlate with the induction of nitric oxide synthase, J. Virol. 67, 5786-5791 (1993).
58. D. C. Hooper, S. T. Ohnishi, R. Kean, Y. Numagami, B. Dietzschold, and H. Koprowski, Local nitric oxide production in viral and autoimmune diseases of the central nervous system, Proc. Natl. Acad. Sci. USA 92, 5312-5316 (1995).
59. I. L. Campbell, A. Samimi, and C. S. Chiang, Expression of the inducible nitric oxide synthase. Correlation with neuropathology and clinical features in mice with lymphocytic choriomeningitis, J. Immunol. 153, 3622-3629 (1994).
60. V. L. Dawson, and T. M. Dawson, Free radicals and neuronal cell death, Cell Death Differ. 3, 71-78 (1996).
61. E. A. Butz, B. S. Hostager, and P. J. Southern, Macrophages in mice acutely infected with lymphocytic choriomeningitis virus are primed for nitric oxide synthesis, Microb. Pathog. 16, 283-295 (1994).
62. H. Adler, B. Frech, P. Meier, T. W. Jungi, and E. Peterhans, Noncytopathic strains of bovine viral diarrhea virus prime bovine bone marrow-derived macrophages for enhanced generation of nitric oxide, Biochem. Biophys. Res. Commun. 202, 1562-1568 (1994).
63. M. I. Bukrinsky, H. S. Nottet, H. Schmidtmayerova, L. Dubrovsky, C. R. Flanagan, M. E. Mullins, S. A. Lipton, and H. E. Gendelman, Regulation of nitric oxide synthase activity in human immunodeficiency virus Type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease, J. Expl. Med. 181, 735-745 (1995).
64. V. L. Dawson, T. M. Dawson, G. R. Uhl, and S. H. Snyder, Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures, Proc. Natl. Acad. Sci. USA 90, 3256-3259 (1993).
65. M. G. Hayman, Arbuthnott, G. Harkiss, H. Brace, P. Filippi, V. Philippon, D. Thomson, R. Vigne, and A. Wright, Neurotoxicity of peptide analogues of the transactivating protein Tat from Maedi-Visna virus and human immunodeficiency virus, Neuroscience 53, 1-6 (1993).
66. V. Philippon, C. Vellutini, D. Gambarelli, G. Harkiss, G. Arbuthnott, D. Metzger, R. Roubin, and P. Filippi, The basic domain of the Lentiviral Tat protein is responsible for damages in mouse brain: involvement of cytokines, Virology 205, 519-529 (1994).
67. K. D. Croen, Evidence for antiviral effect of nitric oxide, inhibition of herpes simplex virus type 1 replication, J. Clin. Invest. 91, 2446-2452 (1993).
68. J. B. Mannick, The antiviral role of nitric oxide, Res. Immunol. 146, 693-697 (1995).
69. G. Karupiah, Q. W. Xie, R. M. L. Buller, C. Nathan, C. Duarte, and J. D. Macmicking, inhibition of viral replication by interferon-gamma induced nitric oxide synthase, Science 261, 1445-1448 (1993).
70. K. Akarid, M. Sinet, B. Desforges, and M. A. Gougerot Pocidalo, Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo, J. Virol. 69, 7001-7005 (1995).
71. Z. B. Bi, and C. S. Reiss, Inhibition of vesicular stomatitis virus infection by nitric oxide, J. Virol. 69, 2208-2213 (1995).
72. M. A. Beck, P. C. Kolbeck, L. H. Rohr, Q. Shi, V. C. Morris, and O. A. Levander, Vitamin E deficiency intensifies the myocardial injury of Coxsackievirus B3 infection of mice, J. Nutr. 124, 345-358 (1994).
73. M. A. Beck, P. C. Kolbeck, L. H. Rohr, Q. Shi, V. C. Morris, and O. A. Levander, Benign Human Enterovirus Becomes Virulent in Selenium-Deficient Mice, J. Med. Virol. 43, 166-170 (1994).
74. M. A. Beck, Q. Shi, V. C. Morris, and O. A. Levander, Rapid genomic evolution of a non-virulent Coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates, Nature Med. 1, 433-436 (1995).
75. M. Brugh, Jr., Butylated hydroxytoluene protects chickens exposed to Newcastle disease virus, Science 197, 1291-1292 (1977).